Meeting
2023 ASCO Genitourinary Cancers Symposium
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Authors
Tanya Jindal
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Tanya Jindal , Deepak Kilari , Omar Alhalabi , Amanda Nizam , Ali Raza Khaki , Arnab Basu , Pedro C. Barata , Mehmet Asim Bilen , Sumit Shah , Yousef Zakharia , Matthew I. Milowsky , Joaquim Bellmunt , Hamid Emamekhoo , Nancy B. Davis , Petros Grivas , Shilpa Gupta , Christopher J. Hoimes , Matthew T Campbell , Ajjai Shivaram Alva , Vadim S Koshkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 450)
DOI
10.1200/JCO.2023.41.6_suppl.450
Abstract #
450
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
First Author: Kevin R Reyes
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
First Author: Alexandra Androsova
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel